Ownership history in Eversept Partners, LP Β· 11 quarters on record
This page tracks every 13F SEC filing in which Eversept Partners, LP reported a position in SUTRO BIOPHARMA INC (STRO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Eversept Partners, LP underperformed the S&P 500 by β38.2% annually on this STRO position. Timing score: 56% (5/9 decisions correct). Average cost basis: $24.05. Maximum drawdown during holding period: β88.5%.
β Significantly underperformed the S&P 500 by 38.2% ann.
10 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
5 of 9 add/trim decisions correct
Best entry: $6.50 (2025 Q1) Β· Worst: $56.50 (2024 Q1)
πͺ Held through 2 major drawdowns (>20%).
7 adds Β· 3 trims. Bought during 3 of 4 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.11% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size